Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis

• Market Cap: HK$2.15B
• Dividend Yield: N/A
• Average Volume (3M): 127.28K
• Price to Earnings (P/E): 46.1
• Beta (1Y): 1.30
• Revenue Growth: 32.93%
• EPS Growth: N/A
• Country: HK
• Employees: 344
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.44
• Shares Outstanding: 31,565,804
• 10 Day Avg. Volume: 119,990
• 30 Day Avg. Volume: 127,280
• PEG Ratio: 0.67
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 2.80
• P/FCF Ratio: -92.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$61.00
• Price Target Upside: 10.21% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: HK$61.00 ▲(10.21% Upside)

The overall stock score of 57 reflects a company with strong revenue growth and a solid balance sheet but facing challenges in profitability and valuation. Technical indicators suggest mixed signals, with short-term weakness but potential long-term strength. The high P/E ratio indicates potential overvaluation, and the lack of a dividend yield may deter income-focused investors. The absence of earnings call and corporate events data limits further insights.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Shanghai Heartcare Medical Technology Corp. Ltd. generates revenue through the sale of its cardiovascular medical devices and solutions to hospitals, clinics, and healthcare providers. The company invests in research and development to continuously innovate and enhance its product offerings, ensuring they meet the evolving needs of the medical community. Additionally, the company may engage in strategic partnerships and collaborations with other healthcare and medical technology firms to expand its market reach and distribution channels. Factors such as advancements in medical technology, increasing demand for minimally invasive procedures, and the growing prevalence of cardiovascular diseases contribute to the company's earnings potential.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview

Summary

The company shows strong revenue growth and a stable balance sheet with low leverage and high liquidity. However, persistent net losses and negative cash flow highlight the need for improved profitability and cash management strategies.

Income Statement

The company has shown a positive revenue growth trajectory with a significant increase in total revenue over the years. Gross profit margin is healthy, but the net profit margin remains negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins are also negative, showing operational inefficiencies.

Balance Sheet

The balance sheet is strong with a high equity ratio and low debt-to-equity ratio, indicating financial stability and low leverage. However, the company has been experiencing net losses, affecting its return on equity negatively. High cash reserves provide a strong liquidity position.

Cash Flow

The company has faced challenges in generating positive operating cash flow, with negative free cash flow indicating difficulties in covering capital expenditures. The absence of positive cash flow metrics suggests a need for better cash management and operational efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	277.90M	232.34M	183.03M	90.09M	14.56M
Gross Profit	181.72M	151.79M	124.33M	54.95M	7.09M
EBITDA	21.87M	-68.50M	-167.31M	-183.34M	-206.19M
Net Income	-13.62M	-94.01M	-200.38M	-194.22M	-213.66M
Balance Sheet
Total Assets	1.21B	1.20B	1.31B	1.50B	773.63M
Cash, Cash Equivalents and Short-Term Investments	713.72M	721.14M	870.12M	1.22B	632.42M
Total Debt	35.75M	36.38M	50.69M	41.94M	24.69M
Total Liabilities	144.00M	125.60M	147.08M	132.10M	82.60M
Stockholders Equity	1.06B	1.08B	1.17B	1.37B	681.37M
Cash Flow
Free Cash Flow	-8.39M	-137.72M	-304.01M	-260.33M	-90.42M
Operating Cash Flow	-3.23M	-88.41M	-266.77M	-205.85M	-74.81M
Investing Cash Flow	10.80M	-125.45M	44.84M	-161.10M	-4.53M
Financing Cash Flow	-12.38M	-21.48M	-24.75M	821.25M	686.22M

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 55.35
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Neutral. The current price of 55.35 is below the 20-day moving average (MA) of 62.60, below the 50-day MA of 60.24, and above the 200-day MA of 38.72, indicating a neutral trend. The MACD of -0.82 indicates Positive momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of 10.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6609.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1302	62 Neutral	HK$8.68B	112.92	1.98%	―	3.42%	-70.82%
6609	57 Neutral	HK$2.15B	46.09	3.84%	―	32.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2500	50 Neutral	HK$1.18B	―	-26.80%	―	-8.56%	-14.84%
2160	49 Neutral	HK$2.99B	563.64	0.22%	―	-4.38%	―
2235	42 Neutral	HK$3.00B	―	-1.39%	―	49.86%	80.35%
9996	41 Neutral	€4.09B	―	-11.20%	―	29.25%	9.02%

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events

Shanghai Heartcare Approves Capital Reserve Utilization to Offset Losses

Shanghai Heartcare Medical Technology Corp. Ltd. held its 2025 second extraordinary general meeting (EGM) where shareholders approved the utilization of the company’s capital reserve to offset losses amounting to RMB575,082,245.74. The resolution was passed unanimously, indicating strong shareholder support for the company’s financial management strategy, which could positively impact its financial stability and market confidence.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Reports Strong Financial Turnaround in H1 2025

Shanghai HeartCare Medical Technology Corporation Limited reported a significant financial turnaround for the first half of 2025, with a 44.4% increase in revenue to RMB185.5 million and a net profit of RMB50.9 million, reversing a loss from the previous year. This improvement is attributed to the successful launch of new hemorrhagic stroke treatment devices, increased sales of existing products, and effective cost control measures. The company is also enhancing its product offerings with new approvals and expanding its international presence through product registrations in multiple countries.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai Heartcare Schedules Board Meeting to Review Interim Results

Shanghai Heartcare Medical Technology Corp. Ltd. has announced an upcoming board meeting scheduled for August 29, 2025. The meeting will address the approval of the company’s interim results for the first half of 2025 and the consideration of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

Shanghai HeartCare Expects Significant Profit Increase in 2025

Shanghai HeartCare Medical Technology Corporation Limited has issued a positive profit alert, expecting a net profit of not less than RMB40 million for the first half of 2025. This financial turnaround is attributed to increased revenue from new and existing stroke treatment devices, effective cost control measures, and gains in financial assets. The company is still finalizing its interim results, and the figures are subject to adjustments.

Shanghai HeartCare to Address Financial Losses at 2025 EGM

Shanghai HeartCare Medical Technology Corporation Limited has announced the convening of its 2025 second extraordinary general meeting (EGM) to be held on August 29, 2025. The primary agenda is to consider and approve the utilization of the company’s capital reserve to offset significant losses amounting to RMB575,082,245.74. This move is in accordance with the company’s Articles of Association and relevant laws, indicating a strategic financial decision aimed at stabilizing the company’s financial standing.

Shanghai HeartCare Expects Profitable Turnaround and Plans Capital Reserve Utilization

Shanghai HeartCare Medical Technology Corporation Limited announced a positive profit alert, expecting a net profit of not less than RMB40 million for the first half of 2025, marking a significant turnaround from a net loss in the same period of 2024. This improvement is attributed to business growth and a decrease in the expense ratio. Additionally, the company proposes to utilize its capital reserve to offset losses, pending shareholder approval at an upcoming extraordinary general meeting.

Shanghai Heartcare Announces Changes in Supervisory Committee

Shanghai Heartcare Medical Technology Corp. Ltd. announced a change in its supervisory committee with the appointment of Mr. Liu Hongbao as the new Employee Representative Supervisor. This change follows the resignation of Mr. Liu Baiwei due to personal work arrangements, who also served as the Chairman of the Supervisory Committee. The company expressed gratitude for Mr. Liu Baiwei’s contributions and clarified that there are no disagreements or pending claims related to his resignation. Mr. Liu Hongbao, who has extensive experience in sales and marketing of medical devices, will not receive remuneration for his role as Employee Representative Supervisor.

Shanghai HeartCare Announces H Share Register Closure for 2025 EGM

Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from July 30, 2025, to August 29, 2025, to determine shareholders eligible to attend and vote at the 2025 second extraordinary general meeting scheduled for August 29, 2025. This move is significant for shareholders as it dictates the timeline for share transfers and eligibility to participate in the company’s decision-making process during the EGM.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.